Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70863 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Tim Heise und 10 weiteren Autor:innen. Beteiligte Einrichtung: Profil, Neuss, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting GIP receptor agonist macupatide, dulaglutide or both combined. Insulin sensitivity ( M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12‐week treatment.
Results
Overall baseline means were cDI, 0.3 pmol*m −2 *L*min −2 *kg −1 ; M value, 5.8 mg*kg −1 *min −1 ; ISR, 116.8 pmol*min −1 *m −2 . The 12‐week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%). Macupatide alone significantly increased the M value and, to a lesser yet significant extent, ISR. Combination therapy was numerically greater than both monotherapies in augmenting all indices. The most frequent adverse events were injection site reactions and diarrhoea. Study discontinuations due to treatment‐emergent adverse events were uncommon. There were no deaths during the study.
Conclusion
These findings demonstrate that chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity, and that combining GIP and GLP‐1 receptor agonism can augment both insulin secretion and insulin sensitivity compared to GLP‐1 therapy alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Profil, Neuss, Germany.
- Institute of Neuroscience, National Research Council (CNR) of Padova, Padova, Italy.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
ORCID-Profile: Tim Heise, Eric Zijlstra, Kieren J Mather, Axel Haupt, Edward J Pratt
Förderung
- Eli Lilly and Company
Zitieren
APA
Heise, T., Zijlstra, E., Mari, A., Roell, W. C., Mather, K. J., Haupt, A., Flevaris, P., Liao, R., Chua, L., Harris, C., & Pratt, E. J. (2026). Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70863
Vancouver
Heise T, Zijlstra E, Mari A, Roell WC, Mather KJ, Haupt A, et al. Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70863
BibTeX
@article{Heise2026,
author = {Heise, Tim and Zijlstra, Eric and Mari, Andrea and Roell, William C and Mather, Kieren J and Haupt, Axel and Flevaris, Panagiotis and Liao, Ran and Chua, Laiyi and Harris, Charles and Pratt, Edward J},
title = {Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70863}
}
EUVIMED